Data / Research funding / Washington / Talus Bioscience, Inc.
Talus Bioscience, Inc.: 5 NIH awards ($5.1M), fiscal years 2021 to 2026
Talus Bioscience, Inc. in Seattle, WA is funded under 5 NIH awards ($5.1M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NKSRDDRQK175
- State
- Washington
Awards
5 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | July 1, 2023 | June 30, 2025 | FEDERATION, ALEXANDER | reporter.nih.gov |
| Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $1,951,023 | August 14, 2023 | January 31, 2026 | FEDERATION, ALEXANDER | reporter.nih.gov |
| Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer | NIH | National Cancer Institute | 2022 | $455,000 | April 1, 2022 | March 31, 2023 | FEDERATION, ALEXANDER | reporter.nih.gov |
| Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins | NIH | National Institute of General Medical Sciences | 2023 | $398,441 | September 20, 2023 | August 31, 2024 | FONDRIE, WILLIAM ELLIS | reporter.nih.gov |
| Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding | NIH | National Center for Advancing Translational Sciences | 2022 | $333,867 | April 1, 2022 | June 30, 2023 | FEDERATION, ALEXANDER | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 1 | $821,779 | 0 | $0 |
| 2024 | 2 | $1,821,779 | 0 | $0 |
| 2023 | 3 | $1,705,906 | 0 | $0 |
| 2022 | 2 | $788,867 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.393 | November 2, 2026 | Not listed | Same assistance listing 93.393 as 2 awards here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NIH | 93.393 | November 6, 2026 | $350,000 | Same assistance listing 93.393 as 2 awards here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NIH | 93.393 | November 17, 2026 | $200,000 | Same assistance listing 93.393 as 2 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.393 | November 20, 2026 | Not listed | Same assistance listing 93.393 as 2 awards here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.350 | November 24, 2026 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.350 | January 5, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.350 | January 5, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.393 | January 7, 2027 | $375,000 | Same assistance listing 93.393 as 2 awards here |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | PAR-25-069 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 2 awards here |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | PAR-25-070 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 2 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.393 | January 7, 2027 | $499,999 | Same assistance listing 93.393 as 2 awards here |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR-25-167 | NIH | 93.393 | January 7, 2027 | Not listed | Same assistance listing 93.393 as 2 awards here |
| HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) | RFA-NS-25-023 | NIH | 93.393 | January 15, 2027 | $350,000 | Same assistance listing 93.393 as 2 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.393 | January 25, 2027 | Not listed | Same assistance listing 93.393 as 2 awards here |
| Clinical and Translational Science Award | PAR-28-002 | NIH | 93.350 | January 25, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant for the Clinical and Translational Science Awards Program | PAR-28-004 | NIH | 93.350 | January 25, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Limited Competition: Research Education Program for the Clinical and Translational Science Awards Program | PAR-28-005 | NIH | 93.350 | January 25, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science | PAR-28-006 | NIH | 93.350 | January 25, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| The Next Generation of the Clinical and Translational Science Awards Program Trial Innovation Network | PAR-28-007 | NIH | 93.350 | January 25, 2027 | Not listed | Same assistance listing 93.350 as 2 awards here |
| Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) | RFA-CA-26-010 | NIH | 93.393 | January 25, 2027 | Not listed | Same assistance listing 93.393 as 2 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.